Stay updated on IMCgp100 vs Investigator Choice in Uveal Melanoma Clinical Trial
Sign up to get notified when there's something new on the IMCgp100 vs Investigator Choice in Uveal Melanoma Clinical Trial page.

Latest updates to the IMCgp100 vs Investigator Choice in Uveal Melanoma Clinical Trial page
- Check2 days agoChange DetectedThe page now lists Revision: v3.0.2, replacing v3.0.1, and the Back to Top link has been removed.SummaryDifference0.1%
- Check9 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.1%
- Check16 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new drug information and resources related to uveal melanoma, as well as the inclusion of various facility names and locations across multiple countries. Notably, the previous drug information for Dacarbazine and Ipilimumab has been removed.SummaryDifference6%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check38 days agoChange DetectedThe page has been updated to reflect the latest version as v2.16.11, replacing the previous version v2.16.10. The phrasing regarding the last update has also changed from 'Estimated' to a definitive statement.SummaryDifference0.1%
- Check45 days agoChange DetectedThe web page has been updated to reflect new eligibility criteria for clinical study participants, including specific conditions regarding prior treatments and health status. Additionally, the last update date has been revised to reflect the most current information.SummaryDifference2%
Stay in the know with updates to IMCgp100 vs Investigator Choice in Uveal Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMCgp100 vs Investigator Choice in Uveal Melanoma Clinical Trial page.